Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice

Table 2: Protection by topical administration of C5A against vaginal and rectal HIV challenges.

C5A Conc. (μM)	% Protection (n=10)
C5A Conc. (μM)	Vaginal	Rectal
6.25	0% (0/10)	0% (0/10)
12.5	0% (0/10)	0% (0/10)
25	30% (3/10)	50% (5/10)
50	80% (8/10)	80% (8/10)
100	100% (10/10)	100% (10/10)
200	100% (10/10)	100% (10/10)